PCSK9 and hyperlipidemia: It has been confirmed that gain-of-function mutations of PCSK9 lead to increased risks of hyperlipidemia and ASCVDs, whereas loss-of-function mutations of PCSK9 reduced plasma levels of LDL-C and ASCVDs risk (Figure 2) (66–68).